A new test lets doctors more accurately identify the right antibiotics to treat serious, chronic infections that are biofilm based. For people with cystic fibrosis, that’s good news.
More than 80 per cent of infections are caused by biofilms. This new breakthrough test,
bioFILM PATM, is of immense significance to the medical community.
![]() |
Agress® is a novel seed treatment developed by Innovotech that is currently going through registration in the USA and Canada.
Agress™ is a novel seed treatment developed by Innovotech that is currently going through registration in the USA and Canada. It is designed for use initially in pulse crops (such as dry beans and soybeans) as a bactericide and fungicide. Using silver, which naturally occurs in the environment at levels above those used in Agress™, the seed treatment is environmentally friendly while demonstrating superior efficacy. Currently developed as a seed treatment, the use of Agress™ is being expanded to fit a host of needs across the agriculture sector.
![]() |
|
The US National Institute of Health estimates that greater than 80% of clinical infections are caused by biofilms. This includes heart and middle ear infections, wound infections, and illnesses associated with implanted medical devices as well as tooth decay and gum disease.
Innovotech's matrix driven experimental systems allow for rapid high throughput screening and antimicrobial R&D for a variety of systems and applications. The MBEC™ assay and the BEST™ system can be used for investigating disinfectants, antimicrobial coatings, and many other applications covering the full range from development through regulatory submission to post-market analysis.
Our labs perform all testing in compliance with GLP. Innovotech is certified under the ISO 13485:2003 quality system.
New Silver Technology Kills Biofilms
January 10, 2012,
Innovation Anthology
The Cutting Edge: Where BioMed and BioTech Intersect
September 28, 2011
World Talk Radio website
"Innovotech product wins international seal of approval",
April 21, 2011
Edmonton Journal